Recent studies reveal that DARZALEX FASPRO® significantly enhances MRD negativity and progression-free survival in newly diagnosed multiple myeloma patients, transforming treatment outcomes.

A recent Phase 3 study indicates that a combination of TECVAYLI and DARZALEX FASPRO enhances survival rates in multiple myeloma patients, showcasing groundbreaking therapeutic advancements.

The FDA's recent approval of DARZALEX FASPRO® marks a significant milestone in treating high-risk smoldering multiple myeloma, enabling earlier intervention.

New data reveals that DARZALEX FASPRO® significantly reduces the risk of progression to active multiple myeloma for high-risk patients, offering hope for frontline treatment.

The FDA's Oncologic Drugs Advisory Committee has voted 6-2 in favor of DARZALEX FASPRO® for treating high-risk smoldering multiple myeloma, potentially changing patient care.

The FDA has approved DARZALEX Faspro® for adult patients with high-risk smoldering multiple myeloma, enabling earlier intervention and better outcomes.

Recent data from Johnson & Johnson highlights the effectiveness of dual induction therapy using TECVAYLI® and DARZALEX FASPRO® for newly diagnosed multiple myeloma patients eligible for transplants.

Recent studies reveal impressive data on DARZALEX FASPRO® showing a 95% progression-free survival rate at four years for newly diagnosed multiple myeloma patients.

The recent approval by the European Commission for DARZALEX Faspro® signifies a major advancement in treating smouldering multiple myeloma at risk patients, enhancing early intervention opportunities.